60 Degrees Pharmaceuticals, Inc.
SXTP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001946563
No open-market purchases or sales by 60 Degrees Pharmaceuticals, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $614.8K in total; no superinvestor holds it.
Other share classesSXTPW
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by 60 Degrees Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for 60 Degrees Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Dow Geoffrey S | President and CEO | 24,131 | Jun 15, 2026 | 3 |
| Landon Kristen | Chief Operating Officer | 4,540 | Aug 14, 2025 | 0 |
| Xu Cheryl | Director | 15,816 | Jun 5, 2025 | 0 |
| Miller Tyrone | CFO | 26,370 | Jan 24, 2025 | 0 |
| Toovey Stephen | Director | 14,000 | May 21, 2024 | 0 |
| Field Paul | Director | 14,000 | May 21, 2024 | 0 |
| Allen Charles W | Director | 14,000 | May 21, 2024 | 0 |
| Knight Therapeutics International SA | Other: Former 10% Owner | 78,803Indirect | Apr 3, 2024 | 0 |
| Knight Therapeutics Inc | Other: Former 10% Owner | 78,803Indirect | Apr 3, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 (view filing) | Jun 12 | 3 days | Dow Geoffrey SPresident and CEO | PPurchase | +7.35K | $1.38 | +$10.1K | +43.8%24.1K after | |
| Dec 16, 2025 (view filing) | Dec 15 | 1 day | Dow Geoffrey SPresident and CEO | PPurchase | +9.67K | $0.80 | +$7.74K | +19.4%59.6K after | |
| Dec 12, 2025 (view filing) | Dec 10-11 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +13.0K | $0.9416 | +$12.2K | +35.0%49.9K after | 2 lots |
| Jun 5, 2025 (view filing) | Jun 3 | 2 days | Xu CherylDirector | PPurchase | +5.00K | $2.88 | +$14.4K | +46.2%15.8K after | 2 lots |
| Dec 18, 2024 (view filing) | Dec 12-16 | 6 daysLate | Xu CherylDirector | PPurchase | +13.0K | $1.65 | +$21.4K | +31.6%54.1K after | 7 lots |
| Dec 9, 2024 (view filing) | Dec 5-9 | 4 days | Dow Geoffrey SPresident and CEO | PPurchase | +74.0K | $1.21 | +$89.7K | +358.5%94.6K after | 3 lots |
| Nov 21, 2024 (view filing) | Nov 19-21 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +7.00K | $0.9079 | +$6.36K | +51.4%20.6K after | 3 lots |
| Sep 11, 2024 (view filing) | Aug 27 | 15 daysLate | Xu CherylDirector | PPurchase | +5.00K | $1.70 | +$8.50K | +13.9%41.1K after | |
| Feb 2, 2024 (view filing)3:33 PM ET | Jan 31 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +26.0K | $0.375 | +$9.74K | +3.8%703.6K after | |
| Feb 2, 2024 (view filing)3:33 PM ET | Jan 31 | 2 days | Dow Geoffrey SPresident and CEO | PPurchase | +26.0K | $0.01 | +$259.74 | –26.0K after | Derivative |
| Feb 2, 2024 (view filing)3:31 PM ET | Jan 31 | 2 days | Xu CherylDirector | PPurchase | +200.0K | $0.375 | +$75.0K | +88.9%424.9K after | |
| Feb 2, 2024 (view filing)3:31 PM ET | Jan 31 | 2 days | Xu CherylDirector | PPurchase | +200.0K | $0.01 | +$2.00K | –200.0K after | Derivative |